@GlympseBio profile picture
Glympse Bio @GlympseBio

Glympse Bio is now merged with Sunbird Bio!

Joined February 2019
  • Tweets 128
  • Following 41
  • Followers 397
71 Photos and videos
Pinned Tweet
Glympse Bio@GlympseBio
9 Aug 2023
#NEWS: Glympse Bio is now merged with Sunbird Bio! Read the press release: sunbirdbio.com/news/Sunbird-…
2
906
Speaking with @karenjagoda of the Empowered Patient Podcast, CMO Dr. Tram Tran discusses how Glympse’s #diagnostic platform simplifies things in the clinic and for the patient using a simple blood-based test. Listen to the podcast here: empoweredpatientradio.com/di…

Empowered Patient Podcast: Disease Activity and Early Signs of Cancer...

Dr. Tram Tran, the Chief Medical Officer at Glympse Bio, is taking the knowledge about the mechanistic roles protease play in many diseases to develop an injectable biosensor to measure protease...

empoweredpatientradio.com
263
On behalf of the entire team at Glympse, we hope you have a very happy Thanksgiving!
Glympse is developing #technology that can non-invasively measure protein activity to #diagnose and monitor disease. Learn more by viewing the animation on our website: glympsebio.com/technology/
Watch: Dr. Amit Singal (@docamitgs) of @utswcancer discusses the need for early #HCC diagnosis and the #TLM22 data demonstrating that Glympse's biosensor platform can sensitively detect HCC. glympsebio.com/video-aasld-t…
#TLM22 begins today! Glympse and Dr. Amit Singal (@docamitgs) will present a poster on Monday 11/7 from 1-2 PM that demonstrates our biosensors can sensitively detect HCC. We hope to see you then! You can view the poster on our website: glympsebio.com/news/?tx_cate… @AASLDtweets
Glympse will present a poster at @AASLDtweets #TLM22 demonstrating the sensitive detection of #HCC by our novel diagnostic platform. You can see the poster on Monday, Nov. 7 from 1-2 PM and find more information in our announcement: prnewswire.com/news-releases…
1
A recent @HealioGastro article highlights how #NASH is the fastest growing cause of hepatocellular carcinoma (#HCC) in the US and of #livercancer deaths worldwide. Glympse’s platform and diagnostic potential seeks to help reverse this trend. healio.com/news/gastroentero…

NASH ‘fastest growing cause’ of liver cancer death worldwide

Despite global declines in liver cancer mortality attributed to hepatitis B and C, liver cancer mortality rose sharply in the Americas, driven by an increase in nonalcoholic steatohepatitis, accord...

healio.com
3
Glympse celebrated the #autumn season with an #applepicking event! We had a wonderful day spending this quality time together as a team. #teamwork
1
October is #LiverAwarenessMonth. Liver disease takes many forms and can significantly impact a patient's quality of life. Glympse is dedicated to developing diagnostics to help improve treatments for patients with #liverdisease. Learn more from @liverUSA: bit.ly/3fMTcXj
1
#ICYMI, our #CMO Tram Tran, MD, wrote an article for @Tech_Networks about the burden of #liverdisease on the healthcare system and the role #diagnostics like Glympse’s can play in alleviating this. Read Tram’s article here: technologynetworks.com/diagn…

Effective Diagnostics for Liver Disease Are Urgently Needed

As primary care physicians continue to see an increasing number of patients with fatty liver disease, it is important for them to be able to effectively triage these patients to ensure the best...

technologynetworks.com
2
Shout out to our new #CSO, Dr. Jonathan Wilde! Since joining the team earlier this year, Dr. Wilde’s scientific expertise has been integral in the development of our novel protein activity biosensor #diagnostic platform.
2
4
On this week’s episode of @PharmaVoice’s #WomanOfTheWeek podcast, CMO Dr. Tram Tran shares the inspirations that led to her career path in #medicine and work on Glympse’s revolutionary diagnostic technology. Listen to the full episode here: pharmavoice.com/news/woman-o…

Woman of the Week: Glympse Bio’s Dr. Tram Tran

How the chief medical officer of the emerging diagnostic company is using the patient perspective as a guiding light.

pharmavoice.com
CMO Dr. Tram Tran sat down with @MyDocWire to discuss Glympse’s focus on early disease detection for #NASH and improving patient outcomes with its unique protein activity-based diagnostic platform. Watch: youtu.be/CxURIxVFa1E
#TeamGlympse wishes you a safe and happy #IndependenceDay!
Tomorrow, June 24, Dr. Amit Singal (@docamitgs) will present findings at #ILC2022 demonstrating that #Glympse’s biosensor platform can detect #HCC from non-HCC patients with liver cirrhosis from a blood sample. See the poster here: glympsebio.com/wp-content/up…
1
4
On Saturday, June 25, CMO Tram Tran, M.D. will present a poster at @EASLNews’s #ILC2022 demonstrating our novel protease biosensor diagnostic platform’s ability to distinguish NASH vs. healthy patients from a blood sample. See the poster here: glympsebio.com/wp-content/up…
1
4
#Glympse CMO @TramTran_MD spoke with @AnnetteMBoyle of @BioWorld about our @EASLnews #ILC2022 data demonstrating early detection of #HCC from a simple blood test and the importance of this for patients. Read more: bioworld.com/articles/519651…
1
1
Today is International #NASHDay. NASH is a severe form of fatty #liverdisease that affects millions worldwide. At #Glympse, we are developing technologies to improve how we diagnose and monitor NASH, so we can #StopNASHNow. Learn more from @globalliver: international-nash-day.com/
1
10
#Glympse will present two posters on the accuracy of its protease biosensor diagnostic platform in detecting patients with hepatocellular carcinoma (#HCC) at the @EASLnews International Liver Congress 2022 #ILC2022. Find out more: prnewswire.com/news-releases…
5
Load more